Benzinga | Sep 29, 2020 07:07AM EDT

Summit Therapeutics Q2 EPS $(0.23) Down From $(0.21) YoY, Sales $170.00K Up From $156.00K YoY

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.23) per share. This is a 9.52 percent decrease over losses of $(0.21) per share from the same period last year. The company reported $170.00 thousand in sales this quarter. This is a 8.97 percent increase over sales of $156.00 thousand the same period last year.